For the quarter ending 2026-03-31, GNPX had $10,218,400 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -4,461,895 | -3,790,211 | -3,799,239 | -8,639,503 |
| Share-based compensation-The2025Eloc Facility | - | 284,386 | 89,996 | 365,553 |
| Depreciation | - | 0 | 0 | 0 |
| Share-based compensation | 73,432 | -346,417 | 385,106 | 274,146 |
| Prepaid expenses and other | 227,877 | -85,858 | -97,553 | 233,531 |
| Research and development supplies | -299,020 | -45,184 | 76,072 | -275,518 |
| Accounts payable | 911,959 | -876,376 | 688,634 | -143,484 |
| Other current liabilities | 266,904 | 499,305 | -573,256 | 75,641 |
| Net cash used in operating activities | -3,138,457 | -4,098,271 | -3,187,278 | -8,025,660 |
| Disposals of property and equipment | - | 0 | 0 | 0 |
| Reductions to intellectual property | - | 0 | 0 | 0 |
| Net cash provided by investing activities | - | 0 | 0 | 0 |
| Net proceeds from issuances of common stock | 13,356,857 | 10,825,811 | 2,943,749 | 7,770,844 |
| Net cash provided by financing activities | 13,356,857 | 10,825,811 | 2,943,749 | 7,770,844 |
| Net increase in cash and cash equivalents | 10,218,400 | 6,727,540 | -243,529 | -254,816 |
| Cash and cash equivalents, beginning of period | 7,830,855 | 1,103,315 | 1,601,660 | - |
| Cash and cash equivalents, end of period | 18,049,255 | 7,830,855 | 1,103,315 | - |
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)